25 June 2020 : Database Analysis
Effects of Marital Status on Prognosis in Women with Infiltrating Ductal Carcinoma of the Breast: A Real-World 1: 1 Propensity-Matched Study
Tian Lan1ABCDEF*, Yunyan Lu2BCD, Hua Luo1CD, Junling He1BE, Jiawei He1CF, Zujian Hu1EF, Haibin Xu1ADOI: 10.12659/MSM.923630
Med Sci Monit 2020; 26:e923630
Table 2 Impact of marital status on the OS by univariate and multivariate survival analysis before PSM.
| Characteristics | 5-year OS | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Log rank χ2 | P value | HR | 95% CI | P value | ||
| Marital status | 4346.6 | <0.001 | ||||
| Married | 89.6% | Reference | ||||
| Divorced | 84.9% | 1.27 | 1.21–1.32 | <0.001 | ||
| Single | 83.5% | 1.36 | 1.31–1.42 | <0.001 | ||
| Widowed | 71.3% | 1.42 | 1.36–1.48 | <0.001 | ||
| Age | 9737.8 | <0.001 | ||||
| 18–49 | 89.6% | Reference | ||||
| 50–59 | 89.6% | 3.42 | 3.28–3.57 | <0.001 | ||
| 60–69 | 88.9% | 1.51 | 1.46–1.56 | <0.001 | ||
| 70–79 | 82.3% | 1.05 | 1.02–1.09 | 0.001 | ||
| ≥80 | 57.2% | 0.98 | 0.95–1.01 | 0.161 | ||
| Race | 1063.9 | <0.001 | ||||
| White | 86.1% | Reference | ||||
| Black | 78.4% | 1.24 | 1.19–1.29 | <0.001 | ||
| API | 91.0% | 0.75 | 0.71–0.80 | <0.001 | ||
| AI | 83.8% | 1.29 | 1.09–1.53 | 0.004 | ||
| Gender | 108.6 | <0.001 | ||||
| Male | 75.0% | Reference | ||||
| Female | 85.8% | 0.73 | 0.65–0.83 | <0.001 | ||
| Median household income | 701.2 | <0.001 | ||||
| Quartile 1 | 82.1% | Reference | ||||
| Quartile 2 | 85.2% | 0.8 | 0.77–0.82 | <0.001 | ||
| Quartile 3 | 86.8% | 1.01 | 0.98–1.04 | 0.473 | ||
| Quartile 4 | 88.9% | 0.99 | 0.96–1.02 | 0.658 | ||
| Insurance | 122.0 | <0.001 | ||||
| Uninsured | 78.9% | Reference | ||||
| Insured | 85.8% | 0.75 | 0.68–0.82 | <0.001 | ||
| Grade | 3373.4 | <0.001 | ||||
| I | 92.8% | Reference | ||||
| II | 88.0% | 1.24 | 1.17–1.30 | <0.001 | ||
| III | 79.3% | 1.84 | 1.74–1.94 | <0.001 | ||
| Stage | 27296.3 | <0.001 | ||||
| I | 92.9% | Reference | ||||
| II | 85.6% | 1.83 | 1.75–1.90 | <0.001 | ||
| III | 70.1% | 4.52 | 4.31–4.74 | <0.001 | ||
| IV | 32.3% | 10.28 | 9.72–10.88 | <0.001 | ||
| Subtype | 3036.7 | <0.001 | ||||
| HR−/HER2− (triple negative) | 74.3% | Reference | ||||
| HR−/HER2+ (HER2 enriched) | 81.6% | 0.52 | 0.49–0.56 | <0.001 | ||
| HR+/HER2− (Luminal A) | 87.9% | 0.48 | 0.46–0.50 | <0.001 | ||
| HR+/HER2+ (Luminal B) | 86.7% | 0.42 | 0.40–0.44 | <0.001 | ||
| Surgery | 17876.6 | <0.001 | ||||
| No surgery | 44.0% | Reference | ||||
| BCS | 90.8% | 0.42 | 0.40–0.44 | <0.001 | ||
| Mastectomy | 83.6% | 0.48 | 0.46–0.50 | <0.001 | ||
| Radiation | 2212.4 | <0.001 | ||||
| None/unknown | 81.1% | Reference | ||||
| Yes | 89.5% | 0.74 | 0.71–0.76 | <0.001 | ||
| Chemotherapy | 55.0 | <0.001 | ||||
| No/unknown | 86.4% | Reference | ||||
| Yes | 84.8% | 0.78 | 0.75–0.81 | <0.001 | ||
| OS – overall survival; PSM – propensity score matching; HR – hazard ratio; CI – confidence interval. | ||||||